Tentarix biotherapeutics announces the appointment of andrew d. kidd, md, cfa, as ceo

San diego--(business wire)--tentarix biotherapeutics today announced the appointment of andrew kidd, md, as chief executive officer. mr. kidd joins tentarix with a distinguished career of over two decades of executive and biotech experience. he was most recently the president and ceo of aptinyx (nasdaq: aptx), a clinical-stage cns-focused biotech company. his previous experience includes senior leadership roles at baxter international (nyse: bax) and the boston consulting group. “we are excited.
BAX Ratings Summary
BAX Quant Ranking